Dosage forms and methods for enantiomerically enriched or pure bupropion

Abstract

This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as an enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.

What is claimed is: 
     
         1 . A dosage form comprising about 60 mg to about 70 mg of the free base form of (S)-bupropion that is at least 95% enantiomerically pure, or a molar equivalent amount of a salt form of (S)-bupropion that is at least 95% enantiomerically pure. 
     
     
         2 . The dosage form of  claim 1 , wherein the (S)-bupropion is at least 97% enantiomerically pure. 
     
     
         3 . The dosage form of  claim 1 , wherein the (S)-bupropion is at least 99% enantiomerically pure. 
     
     
         4 . The dosage form of  claim 1 , wherein the (S)-bupropion is in the salt form. 
     
     
         5 . The dosage form of  claim 1 , wherein the (S)-bupropion is in the free base form. 
     
     
         6 . The dosage form of  claim 1 , wherein the dosage form provides sustained release of the (S)-bupropion. 
     
     
         7 . The dosage form of  claim 1 , wherein the dosage form is free of dextromethorphan. 
     
     
         8 . The dosage form of  claim 1 , wherein the dosage form is free of any other active pharmaceutical agent other than any (R)-bupropion that is present when the (S)-bupropion is less than 100% enantiomerically pure. 
     
     
         9 . The dosage form of  claim 1 , further comprising microcrystalline cellulose. 
     
     
         10 . The dosage form of  claim 1 , further comprising hydroxypropyl methylcellulose. 
     
     
         11 . The dosage form of  claim 1 , further comprising a binder. 
     
     
         12 . The dosage form of  claim 1 , further comprising a disintegrating agent. 
     
     
         13 . The dosage form of  claim 1 , further comprising a lubricant. 
     
     
         14 . The dosage form of  claim 1 , further comprising magnesium stearate. 
     
     
         15 . The dosage form of  claim 1 , further comprising a coating. 
     
     
         16 . The dosage form of  claim 1 , further comprising sucrose. 
     
     
         17 . The dosage form of  claim 1 , further comprising lactose. 
     
     
         18 . The dosage form of  claim 1 , in the form of a tablet. 
     
     
         19 . The dosage form of  claim 1 , in the form of a pill. 
     
     
         20 . The dosage form of  claim 1 , in the form of a capsule. 
     
     
         21 . The dosage form of  claim 1 , wherein the dosage form is formulated for administration once or twice daily.